Strain Profile
Save

Ligilactobacillus salivarius AP-32

◔ Human-origin
Sequenced
Public genome assembly available

Ligilactobacillus salivarius AP-32 (previously classified as Lactobacillus salivarius AP-32) is a strain that has been evaluated primarily in infant and animal research contexts. Randomized controlled trials have examined its use in infant formula, including gut microbiota composition in young infants. Animal model studies have explored this strain in the context of glycemic markers in diabetic mouse models and antioxidant capacity, in preclinical settings. In vitro work has examined immunomodulatory activity. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.

Where it's been studied

Share of this strain's 6 body-system-tagged papers that concern each system. Research coverage, not measured effect.

Gut 5 papers · 83%
Immune 4 papers · 67%
Brain & Mood 1 paper · 17%
Metabolic 1 paper · 17%
Oral 1 paper · 17%

Symptoms in the research

Share of this strain's 1 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.

Diarrhea 1 paper · 100%
Oral health 1 paper · 100%

Research

6 papers reference this strain in the probiotic database.

Match confidence
2024 RCT
Assessment of the safety and gut microbiota modulation ability of an infant formula containing Bifidobacterium animalis ssp. lactis CP-9 or Lactobacillus salivarius AP-32 and the effects of the formula on infant growth outcomes: insights from a four-month clinical study in infants under two months old
· BMC Pediatrics
 2023 RCT
A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Lactobacillus salivarius AP-32 and Bifidobacterium animalis CP-9 Used Individually in Healthy Infants
· Nutrients
 2021 ANIMAL
Probiotic Enhancement of Antioxidant Capacity and Alterations of Gut Microbiota Composition in 6-Hydroxydopamin-Induced Parkinson’s Disease Rats
· Antioxidants
 2020 ANIMAL
Lactobacillus salivarius AP-32 and Lactobacillus reuteri GL-104 decrease glycemic levels and attenuate diabetes-mediated liver and kidney injury in db/db mice
· BMJ Open Diabetes Research & Care
 2011 IN_VITRO
Heat‐Killed Lactic Acid Bacteria Enhance Immunomodulatory Potential by Skewing the Immune Response toward Th1 Polarization
· Journal of Food Science
 2025 REVIEW
Postbiotics in pediatric clinical practice: position paper from Special Group of Latin American Society of Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN)
· Frontiers in Nutrition
Browse all 6 papers →

Discussion

Be the first to comment.

Sign in to join the discussion.

No comments yet.

Citations

Selected papers that name this strain.

  1. [1]
    Assessment of the safety and gut microbiota modulation ability of an infant formula containing Bifidobacterium animalis ssp. lactis CP-9 or Lactobacillus salivarius AP-32 and the effects of the formula on infant growth outcomes: insights from a four-month clinical study in infants under two months old
    · BMC Pediatrics · 2024
    PMID 39731060 →
  2. [2]
    A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Lactobacillus salivarius AP-32 and Bifidobacterium animalis CP-9 Used Individually in Healthy Infants
    · Nutrients · 2023
    PMID 37571365 →
  3. [3]
    Heat‐Killed Lactic Acid Bacteria Enhance Immunomodulatory Potential by Skewing the Immune Response toward Th1 Polarization
    · Journal of Food Science · 2011
    PMID 22417436 →